[go: up one dir, main page]

HK1211859A1 - Abuse deterrent pharmaceutical composition comprising konjac glucomannan - Google Patents

Abuse deterrent pharmaceutical composition comprising konjac glucomannan

Info

Publication number
HK1211859A1
HK1211859A1 HK15112841.9A HK15112841A HK1211859A1 HK 1211859 A1 HK1211859 A1 HK 1211859A1 HK 15112841 A HK15112841 A HK 15112841A HK 1211859 A1 HK1211859 A1 HK 1211859A1
Authority
HK
Hong Kong
Prior art keywords
pharmaceutical composition
konjac glucomannan
abuse deterrent
deterrent pharmaceutical
abuse
Prior art date
Application number
HK15112841.9A
Other languages
English (en)
Chinese (zh)
Inventor
Krishna Hari Bhandari
Naresh Talwar
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of HK1211859A1 publication Critical patent/HK1211859A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4468Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/888Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK15112841.9A 2012-09-28 2015-12-30 Abuse deterrent pharmaceutical composition comprising konjac glucomannan HK1211859A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2791206A CA2791206A1 (en) 2012-09-28 2012-09-28 Abuse deterrent pharmaceutical formulation
PCT/CA2013/000835 WO2014047731A1 (en) 2012-09-28 2013-09-30 Abuse deterrent pharmaceutical composition comprising konjac glucomannan

Publications (1)

Publication Number Publication Date
HK1211859A1 true HK1211859A1 (en) 2016-06-03

Family

ID=50382806

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112841.9A HK1211859A1 (en) 2012-09-28 2015-12-30 Abuse deterrent pharmaceutical composition comprising konjac glucomannan

Country Status (6)

Country Link
US (2) US20150250886A1 (xx)
EP (1) EP2900272B1 (xx)
CA (2) CA2791206A1 (xx)
ES (1) ES2685965T3 (xx)
HK (1) HK1211859A1 (xx)
WO (1) WO2014047731A1 (xx)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3164117B1 (en) 2014-07-03 2023-09-06 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
ES2809458T3 (es) 2014-07-17 2021-03-04 Pharmaceutical Manufacturing Res Services Inc Forma de dosificación llena de líquido, disuasoria del abuso y de liberación inmediata
US9737609B2 (en) * 2014-08-20 2017-08-22 Professional Compounding Centers Of America (Pcca) Natural suspending agent including a synergistic blend of xanthan gum and konjac powder for oral pharmaceutical suspensions
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
CA3013321A1 (en) 2016-02-08 2017-08-17 SpecGx LLC Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
US11478426B2 (en) 2018-09-25 2022-10-25 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
JP7552275B2 (ja) * 2020-11-13 2024-09-18 マツダ株式会社 自動変速機及び自動変速機の遠心バランス調整方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5745394A (en) 1992-12-30 1994-08-15 Fmc Corporation Readily available konjac glucomannan sustained release excipient
US5498436A (en) 1993-12-30 1996-03-12 Fmc Corporation Coprocessed galactomannan-glucomannan
US6733769B1 (en) 1999-05-06 2004-05-11 Opta Food Ingredients, Inc. Methods for lowering viscosity of glucomannan compositions, uses and compositions
US20030068375A1 (en) * 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
DE10250084A1 (de) * 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en) * 2004-11-24 2006-05-25 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070128285A1 (en) 2005-07-12 2007-06-07 Chikara Jin Pharmaceutical composition for oral administration
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
BRPI0821732A2 (pt) * 2007-12-17 2015-06-16 Labopharm Inc Formulações de liberação controlada , forma de dosagem sólida, e, uso da formulação de liberação controlada
CA2733231A1 (en) 2008-08-07 2010-02-11 Avantor Performance Materials, Inc. Sustained release compositions comprising gums and sugar alcohols

Also Published As

Publication number Publication date
EP2900272A4 (en) 2016-04-13
WO2014047731A1 (en) 2014-04-03
CA2791206A1 (en) 2014-03-28
US20150250886A1 (en) 2015-09-10
ES2685965T3 (es) 2018-10-15
CA2885676A1 (en) 2014-04-03
US20180117158A1 (en) 2018-05-03
EP2900272A1 (en) 2015-08-05
EP2900272B1 (en) 2018-06-06
CA2885676C (en) 2020-11-10

Similar Documents

Publication Publication Date Title
HK1211859A1 (en) Abuse deterrent pharmaceutical composition comprising konjac glucomannan
IL234996A0 (en) Hand-release pharmacy preparations with properties to prevent abuse
IL234997B (en) Immediate release pharmaceutical preparations designed to prevent abuse
IL236648A0 (en) Delayed release abuse prevention pharmaceuticals
HK1210599A1 (en) Abuse deterrent pharmaceutical compositions for controlled release
IL252566B (en) Pharmacy preparations and methods
HK1209638A1 (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
GB201318361D0 (en) Content protection
AU344048S (en) Barrier
EP2895982A4 (en) HARDWARE-FORGET ACCESS PROTECTION
PL2817372T3 (pl) Trwałe kompozycje polihydroksyalkanianowe
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
SG11201405575YA (en) Modified polymer compositions
AU344047S (en) Barrier
HK1210710A1 (en) Pharmaceutical composition comprising rebamipide
AU344050S (en) Barrier
AU344046S (en) Barrier
EP2855590A4 (en) POLYMER COMPOSITION
AU344045S (en) Barrier
ZA201502987B (en) Pharmaceutical composition
EP2885638A4 (en) MOLECULAR NETS
GB201208315D0 (en) Pharmaceutical methods and compositions
AU344049S (en) Barrier
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION